Skip to content

Botulinum Toxin A in the Treatment of Hemifacial Spasm

Does Bilateral Botulinum Toxin A in Patients With Hemifacial Spasm Improve Facial Symmetry Unilateral and Bilateral Injection of Botulinum Toxin A in Patients With Hemifacial Spasm? A Prospective, Randomized, Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03306940
Acronym
BTATHS
Enrollment
50
Registered
2017-10-11
Start date
2017-10-02
Completion date
2018-08-31
Last updated
2017-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemifacial Spasm

Keywords

botulinum toxin A

Brief summary

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups. Group A received unilateral injection while group B received bilateral injection. Patients completed follow-up A researcher record facial videos and analyzed facial symmetry and completed 3 scales.

Detailed description

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups.Patients of unilateral group were injected to the affected side and the dose of botulinum toxin A was 2.5-3.75 units/per site. Patients of bilateral group were injected to the affected side with dose of 2.5-3.75 units/per site and the normal side was injected with dose of 1.25 units/per site. 3 scales for measurement were used.

Interventions

DRUGBotulinum Toxin Type A

patients were injected to the normal side with dose of 1.25 units/per site

Sponsors

Tongji University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of hemifacial spasm * Scott grading III to IV * hemifacial spasm duration of half or more years * last botulinum toxin A application at least 3 months before the start of the study

Exclusion criteria

* history of facial trauma, congenital facial asymmetry, facial nerve microsurgical decompression * bilateral hemifacial spasm * allergies to botulinum toxin A or to any component of the drug * previous treatment with botulinum toxin A fewer than 3 months * the use of drugs that could interfere with neuromuscular transmission or spasm

Design outcomes

Primary

MeasureTime frameDescription
Sunnybrook Facial Grading Systemup to 6 monthsSunnybrook Facial Grading System consists of resting symmetry, symmetry of voluntary movement and synkinesis. Total score = Symmetry of voluntary movement score - Resting symmetry score - Synkinesis score

Secondary

MeasureTime frameDescription
Symmetry Scale for Hemifacial Spasmup to 6 monthsSymmetry Scale for Hemifacial Spasm consists of resting symmetry and symmetry of voluntary movement. Total score =Resting symmetry score + Symmetry of voluntary movement score
Facial Clinimetric Evaluation Scaleup to 6 monthsFacial Clinimetric Evaluation Scale consists of six parts:facial movement,facial comfort,oral function,eye comfort,lacrimal control and social function. Total score = facial movement + facial comfort + oral function + eye comfort + lacrimal control + social function.
The effective duration of botulinum toxin Aup to 6 monthsdegree of amelioration in spasm and the effective duration of botulinum toxin A
Adverse eventsup to 6 monthsAdverse events, including stiff face, difficulty drinking and eating, difficulty controlling parotid and so on.The onset and duration of adverse events.Whether to take intervention to ameliorate adverse events and the efficacy of the intervention

Countries

China

Contacts

Primary ContactLingjing Jin, PhD
1164427300@qq.com+86 02166111310
Backup ContactLibin Xiao, MBA
xiaolibinjiayou@163.com+86 13916266214

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026